Opna Bio S.A.

18 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Opna Immuno-Oncology S.A. (to 2023)

Ending by 2030

Aug 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 6, 2027
The maintenance fee for Heterocyclic Compounds and Uses Thereof (US 10,370,374) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
1 fee due May 7, 2027
The maintenance fee for Compounds and Methods for CD73 Modulation and Indications Therefor (US 11,807,626) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
2 fees due Jun 10 to 30, 2027 · next Jun 10
1 fee due Nov 12, 2027
The maintenance fee for Heterocyclic Compounds and Uses Thereof (US 10,647,716) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,640,509	Program Creation Apparatus, Program Creation Method and Program In force Term ends Aug 16, 2027 · High confidence	In force	Term ends Aug 16, 2027	High confidence
US 9,682,981	Compounds and Methods for Kinase Modulation, and Indications Therefor In force Term ends Apr 20, 2031 · High confidence	In force	Term ends Apr 20, 2031	High confidence
US 8,901,118	Compounds and Methods for Kinase Modulation, and Indications Therefor In force Term ends May 15, 2032 · High confidence	In force	Term ends May 15, 2032	High confidence
US 9,718,847	Heterocyclic Compounds and Uses Thereof In force Term ends Mar 14, 2034 · Medium confidence	In force	Term ends Mar 14, 2034	Medium confidence
US 9,822,109	Heterocyclic Compounds and Uses Thereof In force Ends no later than Mar 14, 2034 · Medium confidence	In force	Ends no later than Mar 14, 2034	Medium confidence
US 10,501,460	Heterocyclic Compounds and Uses Thereof In force Ends no later than Mar 14, 2034 · Medium confidence	In force	Ends no later than Mar 14, 2034	Medium confidence
US 10,519,177	Heterocyclic Compounds and Uses Thereof In force Term ends Mar 14, 2034 · Medium confidence	In force	Term ends Mar 14, 2034	Medium confidence
US 9,771,363	Heterocyclic Compounds and Uses Thereof In force Term ends Sep 19, 2036 · High confidence	In force	Term ends Sep 19, 2036	High confidence
US 9,975,894	Heterocyclic Compounds and Uses Thereof In force Term ends Sep 19, 2036 · High confidence	In force	Term ends Sep 19, 2036	High confidence
US 10,370,374	Heterocyclic Compounds and Uses Thereof In force Ends no later than Sep 19, 2036 · Medium confidence	In force	Ends no later than Sep 19, 2036	Medium confidence

10 of 18 patents shown.

Pro members see all 18.

Pro members: see all 18 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 1 no status recorded

List them